These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32463583)

  • 1. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
    Kuempers C; van der Linde LIS; Reischl M; Vogel W; Stellmacher F; Reck M; Heigener D; Rabe KF; Kirfel J; Perner S; Welker L
    Virchows Arch; 2020 Feb; 476(2):261-271. PubMed ID: 31392467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
    Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
    Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
    Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    Gompelmann D; Sinn K; Brugger J; Bernitzky D; Mosleh B; Prosch H; Geleff S; Blessing A; Tiefenbacher A; Hoetzenecker K; Idzko M; Hoda MA
    J Cancer Res Clin Oncol; 2023 May; 149(5):1747-1754. PubMed ID: 35708777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
    Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV
    J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
    Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
    Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.